Hugh Davis's most recent trade in Aclaris Therapeutics Inc was a trade of 261,600 Employee Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aclaris Therapeutics Inc | Hugh Davis | Director, President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 261,600 | 261,600 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Hugh Davis | Director, President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 74,700 | 74,700 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Hugh Davis | Director, President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2024 | 375,000 | 375,000 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Hugh Davis | Director, President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2024 | 107,000 | 107,000 | - | - | Restricted Stock Units |